Author: Jim Lay

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results

November 13, 2025

Read More
Vaxart to Host Upcoming Conference Calls

November 7, 2025

Read More
Dynavax Enters Exclusive License Agreement for Vaxart’s Novel Oral COVID-19 Vaccine Program

November 5, 2025

Read More
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

October 8, 2025

Read More
Vaxart Appoints W. Mark Watson as Lead Independent Director

September 17, 2025

Read More
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

September 10, 2025

Read More
Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025

September 3, 2025

Read More
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

September 2, 2025

Read More
Vaxart, Inc. Stockholder Fireside Chat

August 21, 2025

Read More
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results

August 13, 2025

Read More